Search Results 1021-1030 of 17020 for monoclonal antibody

1. Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers - Mayo Clinic

   Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC V4.03 or V5.0 for phase II part 2), any history of anaphylaxis, or ...

2. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ - Mayo Clinic

   History of severe allergic or anaphylactic reaction to monoclonal antibody therapy. Confirmed diagnosis of progressive multifocal leukoencephalopathy ...

3. A Study to Evaluate Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant - Mayo Clinic

   History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies;; Known active bacterial, viral (e.g., HIV, hepatitis B ...

4. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab - Mayo Clinic

   History of severe hypersensitivity reaction to any monoclonal antibody. Women of Childbearing Potential (WOCBP) who are pregnant or breastfeeding. Women ...

5. Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies - Mayo Clinic

   For prior biological therapies, eg, monoclonal antibodies with a half-life longer than 3 days, the interval must be at least 28 days prior to the first dose of ...

6. A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - Mayo Clinic

   anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative; and; an anthracycline containing chemotherapy regimen;; for subjects ...

7. Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer - Mayo Clinic

   Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drug ...

8. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

   Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates ...

9. A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer - Mayo Clinic

   ... antibodies and the factors that may determine disease progression and treatment response. ... Plan to initiate treatment with either bi-specific antibody or CAR-T ...

10. Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease - Mayo Clinic

    Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy. Uncontrolled infectious complications not ...